<DOC>
	<DOCNO>NCT00654901</DOCNO>
	<brief_summary>This follow-up Study A3L11 ( NCT00404651 ) . Immunogenicity - To describe antibody persistence follow primary series vaccination either DTaP-IPV-Hep B-PRP~T Infanrix hexa™ . - To describe immunogenicity booster dose DTaP-IPV-HepB-PRP~T subset subject . Safety - To describe safety profile booster dose DTacP-IPV-HepB-PRP~T .</brief_summary>
	<brief_title>Study DTaP-IPV-Hep B-PRP~T Combined Vaccine Following Primary Series DTacP IPV-HepB-PRP-T Infanrix Hexa™</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Toddlers previously include Study A3L11 ( NCT00404651 ) complete threedose primary series vaccination either DTaPIPVHepBPRPT Infanrix hexa™ 2 , 4 6 month age Toddlers 15 18 month ( 456 578 day ) age , inclusive Informed Consent Form sign least one parent legal representative two mandatory witness Able attend schedule visit comply trial procedure . Participation another clinical trial 4 week precede booster vaccination . Planned participation another clinical trial present trial period . Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy . Systemic hypersensitivity vaccine component history life threaten reaction vaccine contain substance . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive last 3 month . Any vaccination 4 week precede booster vaccination . Any vaccination plan next visit . History document pertussis , tetanus , diphtheria , polio , Haemophilus influenzae type b hepatitis B ( HB ) infection ( ) ( confirm either clinically , serologically microbiologically ) . Administration vaccine pertussis , tetanus , diphtheria , polio , Hib , and/or hepatitis B infection ( ) since end participation Study A3L11 . Coagulopathy , thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Known maternal history human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HbsAg ) Hepatitis C seropositivity . Subjects related serious adverse event occur follow threedose primary series administration investigational vaccine reference vaccine Study A3L11 . History seizure . Febrile ( temperature ≥38.0°C ) acute illness day inclusion Known contraindication vaccination pertussis vaccine , i.e . : Encephalopathy ; Temperature &gt; 40.0°C within 48 hour follow vaccine injection , due another identifiable cause primary series ; Inconsolable cry occur &gt; 3 hour within 48 hour follow vaccine injection primary series ; Hypotonic hyporesponsive episode within 48 hour follow vaccine injection primary series ; Seizures without fever within 3 day follow vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Invasive Haemophilus influenzae type b .</keyword>
	<keyword>Haemophilus Influenzae Type B Infection</keyword>
</DOC>